Incyte (INCY) & Crispr Therapeutics (CRSP) Head-To-Head Analysis
Incyte (NASDAQ: INCY) and Crispr Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.
This is a breakdown of current ratings and target prices for Incyte and Crispr Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Incyte presently has a consensus price target of $142.86, indicating a potential upside of 43.07%. Crispr Therapeutics has a consensus price target of $22.38, indicating a potential downside of 16.54%. Given Incyte’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Incyte is more favorable than Crispr Therapeutics.
Institutional and Insider Ownership
90.7% of Incyte shares are owned by institutional investors. Comparatively, 24.5% of Crispr Therapeutics shares are owned by institutional investors. 17.7% of Incyte shares are owned by company insiders. Comparatively, 40.0% of Crispr Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Incyte and Crispr Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Incyte||$1.11 billion||19.06||$104.22 million||($0.80)||-124.81|
|Crispr Therapeutics||$5.16 million||213.13||-$23.17 million||($0.32)||-83.78|
Incyte has higher revenue and earnings than Crispr Therapeutics. Incyte is trading at a lower price-to-earnings ratio than Crispr Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Incyte and Crispr Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Incyte beats Crispr Therapeutics on 9 of the 13 factors compared between the two stocks.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with Analyst Ratings Network's FREE daily email newsletter.